THE SPECTRUM OF GENETIC DEFECTS IN CHRONIC LYMPHOCYTIC LEUKEMIA

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world and shows a remarkable heterogeneity in the clinical course. Understand the genetic basis of CLL may help in clarifying the molecular bases of this clinical heterogeneity. Recurrent chromosomal aberrations at 13q14,...

Full description

Saved in:
Bibliographic Details
Main Authors: Davide Rossi, Marco Fangazio, Gianluca Gaidano
Format: Article
Language:English
Published: PAGEPress Publications 2012-11-01
Series:Mediterranean Journal of Hematology and Infectious Diseases
Online Access:http://www.mjhid.org/index.php/mjhid/article/view/351
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846098126007435264
author Davide Rossi
Marco Fangazio
Gianluca Gaidano
author_facet Davide Rossi
Marco Fangazio
Gianluca Gaidano
author_sort Davide Rossi
collection DOAJ
description Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world and shows a remarkable heterogeneity in the clinical course. Understand the genetic basis of CLL may help in clarifying the molecular bases of this clinical heterogeneity. Recurrent chromosomal aberrations at 13q14, 12q, 11q22-q23 and 17p13, and TP53 mutations are the first genetic lesions identified as drivers of the disease. While some of these lesions are associated with poor outcome (17p13 deletion, TP53 mutations and, to a lesser extent, 11q22-q23 deletion) others are linked to a favorable course (13q14 deletion as sole aberration). Recently, next generation sequencing has revealed additional recurrent alterations in CLL targeting the NOTCH1, SF3B1, and BIRC3 genes. NOTCH1, SF3B1, and BIRC3 lesions provide: i) new insights on the mechanisms of leukemogenesis, tumor progression and chemoresistance in this leukemia; ii) new biomarkers for the identification of poor risk patients, having individually shown correlations with survival in CLL; and iii) new therapeutic targets, especially in the setting of high risk disease. This review will summarize the most important genetic aberrations in CLL and how our improved knowledge of the genome of leukemic cells may translate into improved patients' management.
format Article
id doaj-art-6d0435284f0745e7a26f1d399fd0d505
institution Kabale University
issn 2035-3006
language English
publishDate 2012-11-01
publisher PAGEPress Publications
record_format Article
series Mediterranean Journal of Hematology and Infectious Diseases
spelling doaj-art-6d0435284f0745e7a26f1d399fd0d5052025-01-02T01:58:47ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062012-11-0141e2012076e201207610.4084/mjhid.2012.076243THE SPECTRUM OF GENETIC DEFECTS IN CHRONIC LYMPHOCYTIC LEUKEMIADavide Rossi0Marco FangazioGianluca GaidanoCatholic University ,RomeChronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world and shows a remarkable heterogeneity in the clinical course. Understand the genetic basis of CLL may help in clarifying the molecular bases of this clinical heterogeneity. Recurrent chromosomal aberrations at 13q14, 12q, 11q22-q23 and 17p13, and TP53 mutations are the first genetic lesions identified as drivers of the disease. While some of these lesions are associated with poor outcome (17p13 deletion, TP53 mutations and, to a lesser extent, 11q22-q23 deletion) others are linked to a favorable course (13q14 deletion as sole aberration). Recently, next generation sequencing has revealed additional recurrent alterations in CLL targeting the NOTCH1, SF3B1, and BIRC3 genes. NOTCH1, SF3B1, and BIRC3 lesions provide: i) new insights on the mechanisms of leukemogenesis, tumor progression and chemoresistance in this leukemia; ii) new biomarkers for the identification of poor risk patients, having individually shown correlations with survival in CLL; and iii) new therapeutic targets, especially in the setting of high risk disease. This review will summarize the most important genetic aberrations in CLL and how our improved knowledge of the genome of leukemic cells may translate into improved patients' management.http://www.mjhid.org/index.php/mjhid/article/view/351
spellingShingle Davide Rossi
Marco Fangazio
Gianluca Gaidano
THE SPECTRUM OF GENETIC DEFECTS IN CHRONIC LYMPHOCYTIC LEUKEMIA
Mediterranean Journal of Hematology and Infectious Diseases
title THE SPECTRUM OF GENETIC DEFECTS IN CHRONIC LYMPHOCYTIC LEUKEMIA
title_full THE SPECTRUM OF GENETIC DEFECTS IN CHRONIC LYMPHOCYTIC LEUKEMIA
title_fullStr THE SPECTRUM OF GENETIC DEFECTS IN CHRONIC LYMPHOCYTIC LEUKEMIA
title_full_unstemmed THE SPECTRUM OF GENETIC DEFECTS IN CHRONIC LYMPHOCYTIC LEUKEMIA
title_short THE SPECTRUM OF GENETIC DEFECTS IN CHRONIC LYMPHOCYTIC LEUKEMIA
title_sort spectrum of genetic defects in chronic lymphocytic leukemia
url http://www.mjhid.org/index.php/mjhid/article/view/351
work_keys_str_mv AT daviderossi thespectrumofgeneticdefectsinchroniclymphocyticleukemia
AT marcofangazio thespectrumofgeneticdefectsinchroniclymphocyticleukemia
AT gianlucagaidano thespectrumofgeneticdefectsinchroniclymphocyticleukemia
AT daviderossi spectrumofgeneticdefectsinchroniclymphocyticleukemia
AT marcofangazio spectrumofgeneticdefectsinchroniclymphocyticleukemia
AT gianlucagaidano spectrumofgeneticdefectsinchroniclymphocyticleukemia